Cargando…

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model

BACKGROUND: Numerous oncology combination therapies involving modulators of the cancer immune cycle are being developed, yet quantitative simulation models predictive of outcome are lacking. We here present a model-based analysis of tumor size dynamics and immune markers, which integrates experiment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosinsky, Yuri, Dovedi, Simon J., Peskov, Kirill, Voronova, Veronika, Chu, Lulu, Tomkinson, Helen, Al-Huniti, Nidal, Stanski, Donald R., Helmlinger, Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830328/ https://www.ncbi.nlm.nih.gov/pubmed/29486799 http://dx.doi.org/10.1186/s40425-018-0327-9

Ejemplares similares

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Role of T Cell-To-Dendritic Cell Chemoattraction in T Cell Priming Initiation in the Lymph Node: An Agent-Based Modeling Study
por: Azarov, Ivan, et al.
Publicado: (2019)

Interpretation of metabolic memory phenomenon using a physiological systems model: What drives oxidative stress following glucose normalization?
por: Voronova, Veronika, et al.
Publicado: (2017)

Evaluation of Combination Strategies for the A(2A)R Inhibitor AZD4635 Across Tumor Microenvironment Conditions via a Systems Pharmacology Model
por: Voronova, Veronika, et al.
Publicado: (2021)

Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
por: Kosinsky, Yuri, et al.
Publicado: (2022)

Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis
por: Voronova, Veronika, et al.
Publicado: (2020)

Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis
por: Shulgin, Boris, et al.
Publicado: (2020)

Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development
por: Helmlinger, Gabriel, et al.
Publicado: (2019)

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies
por: Shulgin, Boris, et al.
Publicado: (2016)

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics
por: Mistry, Hitesh B., et al.
Publicado: (2019)

A Physiology-Based Model of Bile Acid Distribution and Metabolism Under Healthy and Pathologic Conditions in Human Beings
por: Voronova, Veronika, et al.
Publicado: (2020)

Cycle Network Model of Prostaglandin H Synthase-1
por: Goltsov, Alexey, et al.
Publicado: (2020)

Understanding pharmacokinetics using realistic computational models of fluid dynamics: biosimulation of drug distribution within the CSF space for intrathecal drugs
por: Kuttler, Andreas, et al.
Publicado: (2010)

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
por: Voronova, Veronika, et al.
Publicado: (2022)

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab
por: Gavrilov, Sergey, et al.
Publicado: (2020)

A workflow for the joint modeling of longitudinal and event data in the development of therapeutics: Tools, statistical methods, and diagnostics
por: Zhudenkov, Kirill, et al.
Publicado: (2022)

Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling
por: Sokolov, Victor, et al.
Publicado: (2020)

Strategies for clinical dose optimization of T cell-engaging therapies in oncology
por: Ball, Kathryn, et al.
Publicado: (2023)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia
por: Sokolov, Victor, et al.
Publicado: (2019)

Agent Based Modeling of Human Gut Microbiome Interactions and Perturbations
por: Shashkova, Tatiana, et al.
Publicado: (2016)

Evaluation of therapeutic strategies targeting BCAA catabolism using a systems pharmacology model
por: Voronova, Veronika, et al.
Publicado: (2022)

Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer
por: Nagase, Mario, et al.
Publicado: (2020)

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use
por: Nayak, Satyaprakash, et al.
Publicado: (2018)

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
por: Renard, Didier, et al.
Publicado: (2011)

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies
por: Boustani, Jihane, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

The CTLA‐4 immune checkpoint protein regulates PD‐L1:PD‐1 interaction via transendocytosis of its ligand CD80
por: Kennedy, Alan, et al.
Publicado: (2023)

Reporting guidelines for population pharmacokinetic analyses
por: Dykstra, Kevin, et al.
Publicado: (2015)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
por: Al‐Huniti, Nidal, et al.
Publicado: (2020)

CT Radiation Dose Optimization and Estimation: an Update for Radiologists
por: Goo, Hyun Woo
Publicado: (2012)

Optimal radiation dose in the neoadjuvant management of esophageal cancer
por: Buckstein, Michael
Publicado: (2020)

The anti-tumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade
por: Dovedi, Simon, et al.
Publicado: (2014)

Optimal Radiation Dose for Stage III Lung Cancer—Should “Definitive” Radiation Doses Be Used in the Preoperative Setting?
por: Saffarzadeh, Areo G., et al.
Publicado: (2021)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

Defining the optimal dose of radiation in leukemic patients with extramedullary lesions
por: Song, Jin Ho, et al.
Publicado: (2011)

Low-Dose Computed Tomography for the Optimization of Radiation Dose Exposure in Patients with Crohn's Disease
por: Kavanagh, Richard G., et al.
Publicado: (2018)

Evaluation of Impact of Factors Affecting CT Radiation Dose for Optimizing Patient Dose Levels
por: Yang, Ching-Ching
Publicado: (2020)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d0r915i9auv9kdmttq2sdd5dck